Semaglutide is a glucagon-like peptide-1 (GLP-1) analog that was approved in 2017 as a treatment method for improving glycemic control in patients with Type 2 diabetes. More recently Semaglutide was approved by the FDA for non-diabetic weight loss. Studies have demonstrated that Semaglutide reduced appetite, improved control of eating, and reduced food cravings in addition to improved glycemic control. The greatest weight loss benefits were observed when Semaglutide is used in combination with lifestyle changes, such as improved diet and consistent exercise.